1. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
- Author
-
De Angelis, Carmine, Fu, Xiaoyong, Cataldo, Maria Letizia, Nardone, Agostina, Pereira, Resel, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Sethunath, Vidyalakshmi, Wang, Tao, Hilsenbeck, Susan G, Benelli, Matteo, Migliaccio, Ilenia, Guarducci, Cristina, Malorni, Luca, Litchfield, Lacey M, Liu, Jiangang, Donaldson, Joshua, Selenica, Pier, Brown, David N, Weigelt, Britta, Reis-Filho, Jorge S, Park, Ben H, Hurvitz, Sara A, Slamon, Dennis J, Rimawi, Mothaffar F, Jansen, Valerie M, Jeselsohn, Rinath, Osborne, C Kent, and Schiff, Rachel
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Genetics ,Breast Cancer ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Good Health and Well Being ,Antineoplastic Agents ,Breast Neoplasms ,Cyclin-Dependent Kinase 4 ,Cyclin-Dependent Kinase 6 ,Female ,Humans ,Piperazines ,Pyridines ,Receptors ,Estrogen ,Signal Transduction ,Tumor Cells ,Cultured ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposeCyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (ER+)/HER2- breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of sensitivity and resistance to CDK4/6i may lead to identification of predictive biomarkers and novel therapeutic targets, paving the way toward improving patient outcomes.Experimental designParental breast cancer cells and their endocrine-resistant derivatives (EndoR) were used. Derivatives with acquired resistance to palbociclib (PalboR) were generated from parental and estrogen deprivation-resistant MCF7 and T47D cells. Transcriptomic and proteomic analyses were performed in palbociclib-sensitive and PalboR lines. Gene expression data from CDK4/6i neoadjuvant trials and publicly available datasets were interrogated for correlations of gene signatures and patient outcomes.ResultsParental and EndoR breast cancer lines showed varying degrees of sensitivity to palbociclib. Transcriptomic analysis of these cell lines identified an association between high IFN signaling and reduced CDK4/6i sensitivity; thus an "IFN-related palbociclib-resistance Signature" (IRPS) was derived. In two neoadjuvant trials of CDK4/6i plus endocrine therapy, IRPS and other IFN-related signatures were highly enriched in patients with tumors exhibiting intrinsic resistance to CDK4/6i. PalboR derivatives displayed dramatic activation of IFN/STAT1 signaling compared with their short-term treated or untreated counterparts. In primary ER+/HER2- tumors, the IRPS score was significantly higher in lumB than lumA subtype and correlated with increased gene expression of immune checkpoints, endocrine resistance, and poor prognosis.ConclusionsAberrant IFN signaling is associated with intrinsic resistance to CDK4/6i. Experimentally, acquired resistance to palbociclib is associated with activation of the IFN pathway, warranting additional studies to clarify its involvement in resistance to CDK4/6i.
- Published
- 2021